• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Continuation of therapeutic dose heparin for critically ill patients with COVID-19.

作者信息

Bradbury Charlotte A, Lawler Patrick R, McVerry Bryan J, Zarychanski Ryan

机构信息

University of Bristol, Bristol, UK.

Bristol Haematology and Oncology Centre, Horfield Road, Bristol, BS2 8ED, UK.

出版信息

Intensive Care Med. 2023 Jul;49(7):873-875. doi: 10.1007/s00134-023-07095-8. Epub 2023 May 31.

DOI:10.1007/s00134-023-07095-8
PMID:37256341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10231279/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cb/10231279/117f8e0091dc/134_2023_7095_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cb/10231279/117f8e0091dc/134_2023_7095_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70cb/10231279/117f8e0091dc/134_2023_7095_Fig1_HTML.jpg

相似文献

1
Continuation of therapeutic dose heparin for critically ill patients with COVID-19.对新冠肺炎重症患者持续使用治疗剂量的肝素。
Intensive Care Med. 2023 Jul;49(7):873-875. doi: 10.1007/s00134-023-07095-8. Epub 2023 May 31.
2
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials.COVID-19 重症患者预防性抗凝治疗中肝素最佳剂量的系统评价和随机对照试验的荟萃分析。
J Crit Care. 2023 Oct;77:154344. doi: 10.1016/j.jcrc.2023.154344. Epub 2023 May 25.
3
The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies.肝素全剂量抗凝对住院非危重症 COVID-19 患者生存的影响：高质量研究的荟萃分析。
Lung. 2023 Apr;201(2):135-147. doi: 10.1007/s00408-023-00599-6. Epub 2023 Feb 4.
4
The landscape of thromboprophylaxis utilization in critically ill children: sparse and variable.
Crit Care Med. 2014 May;42(5):1317-8. doi: 10.1097/CCM.0000000000000185.
5
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
6
Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.危重症患者的药物和机械性血栓预防：12项试验的网状Meta分析
J Korean Med Sci. 2016 Nov;31(11):1828-1837. doi: 10.3346/jkms.2016.31.11.1828.
7
COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?新冠病毒肺炎：为重症患者的血栓预防开启新范式？
Crit Care. 2020 Jun 11;24(1):332. doi: 10.1186/s13054-020-03052-9.
8
COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year.COVID-19 相关凝血功能障碍与抗血栓药物——1 年后的经验教训。
Lancet Haematol. 2021 Jul;8(7):e524-e533. doi: 10.1016/S2352-3026(21)00105-8. Epub 2021 Apr 27.
9
Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.治疗剂量肝素对因 COVID-19 住院患者的治疗效果
JAMA. 2023 Aug 1;330(5):471-472. doi: 10.1001/jama.2023.9535.
10
Effect of sodium citrate anticoagulant solution in continuous veno-venous hemofiltration in critically ill children.枸橼酸钠抗凝溶液在危重症儿童连续性静脉-静脉血液滤过中的作用
BMC Pediatr. 2025 Jul 2;25(1):496. doi: 10.1186/s12887-025-05762-x.

引用本文的文献

1
Hurdles for the Delivery of Multinational Randomized Clinical Trials.开展跨国随机临床试验的障碍。
JAMA Netw Open. 2025 Jul 1;8(7):e2518503. doi: 10.1001/jamanetworkopen.2025.18503.
2
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.氢化可的松对重症社区获得性肺炎患者死亡率的影响：REMAP-CAP皮质类固醇领域随机临床试验
Intensive Care Med. 2025 Apr;51(4):665-680. doi: 10.1007/s00134-025-07861-w. Epub 2025 Apr 22.
3
Predictive Model for Mortality in Severe COVID-19 Patients across the Six Pandemic Waves.

本文引用的文献

1
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
2
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
3
预测模型用于预测 COVID-19 六波大流行期间重症患者的死亡率。
Viruses. 2023 Oct 30;15(11):2184. doi: 10.3390/v15112184.
4
Simvastatin in Critically Ill Patients with Covid-19.辛伐他汀用于新冠肺炎危重症患者
N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25.
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
4
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.